Cipla buys Indian plants from contractor
Indian drugmaker Cipla has bought two manufacturing facilities from its contractor Okasa Pharma.
The INR100m ($16m) deal, which was detailed in a filing on the Bombay Stock Exchange (BSE) on Monday, adds a multi-dosage form plant in Goa and an aerosol formulations site in Satara to Cipla’s network and it being conducted by its subsidiary Medispral Laboratories.
The drugmaker said that: “A significant portion of the capacities of the two undertakings are dedicated for the manufacture of Cipla's products. Acquisition of the aforesaid undertakings is expected to yield operational synergies.”
News of the deal comes just months after Cipla unveiled plans to invest in its UK manufacturing subsidiary and acquired fellow India-based cell banking, cell culture, purification and formulation firm Mabpharm.